Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Paul Bunn to Carcinoma, Non-Small-Cell Lung

This is a "connection" page, showing publications Paul Bunn has written about Carcinoma, Non-Small-Cell Lung.

 
Connection Strength
  
 
 
16.250
  
  1. Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions? Clin Cancer Res. 2022 06 01; 28(11):2204-2205.
    View in: PubMed
    Score: 0.454
  2. Pacheco J, Schenk EL, Bunn PA. Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectr. 2021 06; 5(3).
    View in: PubMed
    Score: 0.414
  3. Bunn PA, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018 09 01; 36(25):2571-2574.
    View in: PubMed
    Score: 0.347
  4. Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 06 01; 124(11):2407-2414.
    View in: PubMed
    Score: 0.340
  5. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 03; 388(10048):1012-24.
    View in: PubMed
    Score: 0.305
  6. Hirsch FR, Bunn PA. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Nat Rev Clin Oncol. 2015 Dec; 12(12):689-90.
    View in: PubMed
    Score: 0.288
  7. Bunn PA, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clin Lung Cancer. 2015 Jul; 16(4):245-51.
    View in: PubMed
    Score: 0.275
  8. Johnson DH, Schiller JH, Bunn PA. Reply to A. Braillon. J Clin Oncol. 2014 Nov 01; 32(31):3575.
    View in: PubMed
    Score: 0.266
  9. Bunn PA, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res. 2014 Apr 01; 20(7):1727-9.
    View in: PubMed
    Score: 0.256
  10. Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. J Clin Oncol. 2014 Apr 01; 32(10):973-82.
    View in: PubMed
    Score: 0.256
  11. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10; 30(32):3909-12.
    View in: PubMed
    Score: 0.233
  12. Bunn PA, Doebele RC. Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol. 2011 May 20; 29(15):1943-5.
    View in: PubMed
    Score: 0.210
  13. Hirsch FR, Wynes MW, Gandara DR, Bunn PA. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11.
    View in: PubMed
    Score: 0.202
  14. Bunn PA. Optimal therapy for elderly patients with early stage non-small cell lung cancer. Am J Respir Crit Care Med. 2010 Feb 01; 181(3):201-2.
    View in: PubMed
    Score: 0.193
  15. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010 Jul; 69(1):1-12.
    View in: PubMed
    Score: 0.193
  16. Hirsch FR, Bunn PA. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009 May; 10(5):432-3.
    View in: PubMed
    Score: 0.183
  17. Bunn PA. Novel therapies for non-small-cell lung cancer: a 2008 update. Clin Lung Cancer. 2009 Mar; 10 Suppl 1:S6.
    View in: PubMed
    Score: 0.181
  18. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25.
    View in: PubMed
    Score: 0.179
  19. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6317-23.
    View in: PubMed
    Score: 0.176
  20. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42.
    View in: PubMed
    Score: 0.172
  21. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist. 2008; 13 Suppl 1:1-4.
    View in: PubMed
    Score: 0.167
  22. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008; 13 Suppl 1:37-46.
    View in: PubMed
    Score: 0.167
  23. Bunn PA. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007 Jun 20; 25(18):2504-5.
    View in: PubMed
    Score: 0.161
  24. Solomon B, Bunn PA. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest. 2007 Jun; 25(4):217-25.
    View in: PubMed
    Score: 0.160
  25. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60.
    View in: PubMed
    Score: 0.158
  26. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
    View in: PubMed
    Score: 0.158
  27. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007 Apr; 18(4):752-60.
    View in: PubMed
    Score: 0.157
  28. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
    View in: PubMed
    Score: 0.155
  29. Bunn PA. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):5919-20.
    View in: PubMed
    Score: 0.154
  30. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Bar?n A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006 Aug; 4(8):521-8.
    View in: PubMed
    Score: 0.151
  31. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4409s-4415s.
    View in: PubMed
    Score: 0.151
  32. Bunn PA, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res. 2006 Jun 15; 12(12):3652-6.
    View in: PubMed
    Score: 0.150
  33. Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol. 2005 Dec 20; 23(36):9044-7.
    View in: PubMed
    Score: 0.144
  34. Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705.
    View in: PubMed
    Score: 0.144
  35. Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol. 2005 May 01; 23(13):2882-3.
    View in: PubMed
    Score: 0.137
  36. Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
    View in: PubMed
    Score: 0.133
  37. Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
    View in: PubMed
    Score: 0.133
  38. Bunn P. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):5-11.
    View in: PubMed
    Score: 0.131
  39. Bunn PA. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4263s-4265s.
    View in: PubMed
    Score: 0.131
  40. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97.
    View in: PubMed
    Score: 0.130
  41. Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38.
    View in: PubMed
    Score: 0.127
  42. Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. J Thorac Oncol. 2024 May; 19(5):719-731.
    View in: PubMed
    Score: 0.126
  43. Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5813-24.
    View in: PubMed
    Score: 0.126
  44. Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Belani CP, Kelly K, Wistuba I. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023 10; 18(10):1290-1302.
    View in: PubMed
    Score: 0.124
  45. Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22.
    View in: PubMed
    Score: 0.123
  46. Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86.
    View in: PubMed
    Score: 0.123
  47. Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
    View in: PubMed
    Score: 0.120
  48. Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
    View in: PubMed
    Score: 0.119
  49. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
    View in: PubMed
    Score: 0.118
  50. Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5.
    View in: PubMed
    Score: 0.116
  51. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002 Sep 15; 20(18 Suppl):23S-33S.
    View in: PubMed
    Score: 0.116
  52. Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022 10; 28(10):2155-2161.
    View in: PubMed
    Score: 0.116
  53. Lin EP, Hsu CY, Berry L, Bunn P, Shyr Y. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses. JAMA Netw Open. 2022 08 01; 5(8):e2227211.
    View in: PubMed
    Score: 0.115
  54. Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
    View in: PubMed
    Score: 0.113
  55. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002 May 06; 86(9):1449-56.
    View in: PubMed
    Score: 0.113
  56. Postmus PE, Bunn PA. Pemetrexed as a single agent in the therapy of advanced lung cancer. Semin Oncol. 2002 Apr; 29(2 Suppl 5):17-22.
    View in: PubMed
    Score: 0.112
  57. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 2002 Mar; 8(3):904-12.
    View in: PubMed
    Score: 0.112
  58. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002 Feb; 29(1 Suppl 4):3-14.
    View in: PubMed
    Score: 0.111
  59. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
    View in: PubMed
    Score: 0.111
  60. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002 Feb; 29(1 Suppl 4):51-8.
    View in: PubMed
    Score: 0.111
  61. Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94.
    View in: PubMed
    Score: 0.111
  62. Bunn PA. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer]. Anticancer Drugs. 2001 Jul; 12 Suppl 3:S3-8.
    View in: PubMed
    Score: 0.106
  63. Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):669-677.
    View in: PubMed
    Score: 0.101
  64. Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
    View in: PubMed
    Score: 0.101
  65. Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S.
    View in: PubMed
    Score: 0.098
  66. Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000 Apr; 117(4 Suppl 1):138S-143S.
    View in: PubMed
    Score: 0.098
  67. Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000 Apr; 117(4 Suppl 1):163S-168S.
    View in: PubMed
    Score: 0.098
  68. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 2000 Mar; 119(3):429-39.
    View in: PubMed
    Score: 0.097
  69. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
    View in: PubMed
    Score: 0.095
  70. Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 2019 03 01; 30(3):447-455.
    View in: PubMed
    Score: 0.091
  71. Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
    View in: PubMed
    Score: 0.090
  72. Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, Robin T, Liu A, Karam S, Gaspar L, Kavanagh B, Rusthoven C, Aisner D, Doebele R, Camidge DR. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 04; 14(4):691-700.
    View in: PubMed
    Score: 0.090
  73. Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Semin Oncol. 1998 Aug; 25(4 Suppl 9):2-10.
    View in: PubMed
    Score: 0.087
  74. Bunn PA. Triplet chemotherapy combinations with new agents: is there a rationale? Semin Oncol. 1998 Aug; 25(4 Suppl 9):55-61.
    View in: PubMed
    Score: 0.087
  75. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, P?rol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
    View in: PubMed
    Score: 0.087
  76. Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 11; 13(11):1717-1726.
    View in: PubMed
    Score: 0.087
  77. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May; 4(5):1087-100.
    View in: PubMed
    Score: 0.085
  78. Kelly K, Bunn PA. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 1998 May; 20(2):85-91.
    View in: PubMed
    Score: 0.085
  79. He Y, Liu S, Mattei J, Bunn PA, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018; 12:981-986.
    View in: PubMed
    Score: 0.085
  80. McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018 07 15; 24(14):3334-3347.
    View in: PubMed
    Score: 0.085
  81. Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67.
    View in: PubMed
    Score: 0.084
  82. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, P?rol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 02; 13(2):165-183.
    View in: PubMed
    Score: 0.083
  83. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
    View in: PubMed
    Score: 0.081
  84. Bunn PA. The emerging role of gemcitabine in lung cancer: part I. Semin Oncol. 1997 Apr; 24(2 Suppl 7):S7-1.
    View in: PubMed
    Score: 0.079
  85. He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 2016 Dec 13; 7(50):82104-82111.
    View in: PubMed
    Score: 0.078
  86. Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
    View in: PubMed
    Score: 0.078
  87. Bunn PA. Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):9-15.
    View in: PubMed
    Score: 0.078
  88. Bunn PA. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):18-25.
    View in: PubMed
    Score: 0.078
  89. Bunn PA. Future directions in therapeutic approaches for small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):136-8.
    View in: PubMed
    Score: 0.078
  90. Scarborough HA, Helfrich BA, Cas?s-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res. 2017 Mar 15; 23(6):1531-1541.
    View in: PubMed
    Score: 0.077
  91. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, P?rol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22.
    View in: PubMed
    Score: 0.075
  92. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63.
    View in: PubMed
    Score: 0.075
  93. Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 06; 96:27-32.
    View in: PubMed
    Score: 0.074
  94. Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist. 2015 Oct; 20(10):1175-81.
    View in: PubMed
    Score: 0.071
  95. Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6.
    View in: PubMed
    Score: 0.071
  96. Bunn PA, Kelly K. New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):53-63.
    View in: PubMed
    Score: 0.070
  97. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
    View in: PubMed
    Score: 0.068
  98. Scarborough HA, Bunn PA, DeGregori J. Personalized one-two punches for lung cancer. Cell Res. 2015 Mar; 25(3):269-70.
    View in: PubMed
    Score: 0.068
  99. Bunn PA. Future directions in clinical research for lung cancer. Chest. 1994 Dec; 106(6 Suppl):399S-407S.
    View in: PubMed
    Score: 0.067
  100. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
    View in: PubMed
    Score: 0.067
  101. Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res. 2014 Sep 01; 20(17):4422-4.
    View in: PubMed
    Score: 0.066
  102. Bunn PA, Chan D, Stewart J, Gera L, Tolley R, Jewett P, Tagawa M, Alford C, Mochzuki T, Yanaihara N. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines. Cancer Res. 1994 Jul 01; 54(13):3602-10.
    View in: PubMed
    Score: 0.066
  103. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol. 1994 Jun; 21(3 Suppl 6):49-59.
    View in: PubMed
    Score: 0.065
  104. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309.
    View in: PubMed
    Score: 0.065
  105. Bunn PA, Van Zandwijk N, Pastorino U, Aisner J, Alberto P, Arriagada R, Carney D, Cornis R, Dittrich C, Gatzemeier U, et al. European School of Oncology. First Euro-American Forum on Lung Cancer Treatment. Eur J Cancer. 1994; 30A(5):710-3.
    View in: PubMed
    Score: 0.063
  106. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236.
    View in: PubMed
    Score: 0.063
  107. Peled N, Zach L, Liran O, Ilouze M, Bunn PA, Hirsch FR. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 2013 Dec; 8(12):e112-3.
    View in: PubMed
    Score: 0.063
  108. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
    View in: PubMed
    Score: 0.059
  109. Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
    View in: PubMed
    Score: 0.058
  110. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55.
    View in: PubMed
    Score: 0.056
  111. Hazuka MB, Bunn PA. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am Rev Respir Dis. 1992 Apr; 145(4 Pt 1):967-77.
    View in: PubMed
    Score: 0.056
  112. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA, Bar?n AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012 Sep 15; 118(18):4502-11.
    View in: PubMed
    Score: 0.055
  113. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73.
    View in: PubMed
    Score: 0.054
  114. Kelly K, Kane MA, Bunn PA. Growth factors in lung cancer: possible etiologic role and clinical target. Med Pediatr Oncol. 1991; 19(6):450-8.
    View in: PubMed
    Score: 0.051
  115. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011 Jan 01; 300(1):66-78.
    View in: PubMed
    Score: 0.051
  116. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010 May 01; 28(13):2174-80.
    View in: PubMed
    Score: 0.049
  117. Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
    View in: PubMed
    Score: 0.049
  118. Bunn PA. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol. 1989 Aug; 16(4 Suppl 6):10-21.
    View in: PubMed
    Score: 0.047
  119. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol. 2009 Mar; 4(3):318-25.
    View in: PubMed
    Score: 0.045
  120. Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Hirsch FR. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol. 2009 Apr; 20(4):689-95.
    View in: PubMed
    Score: 0.045
  121. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009 Jan; 75(1):196-207.
    View in: PubMed
    Score: 0.044
  122. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
    View in: PubMed
    Score: 0.043
  123. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA, Franklin WA. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer. 2008 Mar 01; 112(5):1114-21.
    View in: PubMed
    Score: 0.042
  124. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008 Jun; 19(6):1053-9.
    View in: PubMed
    Score: 0.042
  125. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.041
  126. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 06; 99(11):838-46.
    View in: PubMed
    Score: 0.040
  127. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91.
    View in: PubMed
    Score: 0.040
  128. Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2007 Mar; 18(3):447-52.
    View in: PubMed
    Score: 0.039
  129. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5034-42.
    View in: PubMed
    Score: 0.039
  130. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535.
    View in: PubMed
    Score: 0.039
  131. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
    View in: PubMed
    Score: 0.038
  132. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, J?nne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
    View in: PubMed
    Score: 0.038
  133. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Bar?n AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006 May 15; 12(10):3078-84.
    View in: PubMed
    Score: 0.037
  134. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006 Jul; 17(7):1120-7.
    View in: PubMed
    Score: 0.037
  135. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006 Jan 15; 66(2):944-50.
    View in: PubMed
    Score: 0.036
  136. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005 Dec 12; 93(12):1334-40.
    View in: PubMed
    Score: 0.036
  137. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
    View in: PubMed
    Score: 0.036
  138. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005 Aug 01; 23(22):5007-18.
    View in: PubMed
    Score: 0.035
  139. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45.
    View in: PubMed
    Score: 0.035
  140. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005 May 04; 97(9):643-55.
    View in: PubMed
    Score: 0.035
  141. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Bar?n AE, Zeng C, Johnson TK, Bunn PA. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):795-805.
    View in: PubMed
    Score: 0.034
  142. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46.
    View in: PubMed
    Score: 0.033
  143. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
    View in: PubMed
    Score: 0.033
  144. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
    View in: PubMed
    Score: 0.033
  145. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Bar?n AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003 Oct 15; 21(20):3798-807.
    View in: PubMed
    Score: 0.031
  146. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA, Thompson WJ. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003 May; 2(5):479-88.
    View in: PubMed
    Score: 0.030
  147. Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May; 8(5):1280-7.
    View in: PubMed
    Score: 0.028
  148. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8.
    View in: PubMed
    Score: 0.027
  149. Bunn PA. Triplet combination chemotherapy and targeted therapy regimens. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):26-32.
    View in: PubMed
    Score: 0.026
  150. Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
    View in: PubMed
    Score: 0.026
  151. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15; 59(24):6178-84.
    View in: PubMed
    Score: 0.024
  152. Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 1998 Nov; 4(11):2849-58.
    View in: PubMed
    Score: 0.022
  153. Pisters KM, Kris MG, Bunn PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-41-S12-44.
    View in: PubMed
    Score: 0.020
  154. Bunn PA. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-153-S12-162.
    View in: PubMed
    Score: 0.020
  155. Cohen AJ, Skidgel RA, Gilman LB, Black JK, Bunn PA, Helfrich B, Franklin WA, Miller YE. Carboxypeptidase M. Variable expression in normal human lung and inactivation in lung cancer. Chest. 1997 Jun; 111(6 Suppl):149S.
    View in: PubMed
    Score: 0.020
  156. Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996 Feb 15; 56(4):831-9.
    View in: PubMed
    Score: 0.018
  157. Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol. 1994 Sep; 12(9):1814-20.
    View in: PubMed
    Score: 0.017
  158. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 01; 119(13):2383-90.
    View in: PubMed
    Score: 0.015
  159. Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013; 339-46.
    View in: PubMed
    Score: 0.015
  160. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res. 1992 Sep 01; 52(17):4752-7.
    View in: PubMed
    Score: 0.014
  161. Cas?s-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15; 72(16):4154-64.
    View in: PubMed
    Score: 0.014
  162. Bunn PA. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol. 1992 Feb; 19(1 Suppl 2):1-11.
    View in: PubMed
    Score: 0.014
  163. Hazuka MB, Bunn PA, Crowley J. Maximum tolerated dose for low-dose continuous infusion cisplatin. Int J Radiat Oncol Biol Phys. 1991 Aug; 21(3):869-70.
    View in: PubMed
    Score: 0.013
  164. Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr; 16(2 Suppl 5):27-33.
    View in: PubMed
    Score: 0.011
  165. Mulvin DW, Howard RB, Mitchell DH, Noker PE, Kruse CA, Chu HD, Bunn PA, Johnston MR. Secondary screening system for preclinical testing of human lung cancer therapies. J Natl Cancer Inst. 1992 Jan 01; 84(1):31-7.
    View in: PubMed
    Score: 0.003
  166. Lear JL, Kasliwal RK, Feyerabend AJ, Pratt JP, Bunn PA, Dienhart DG, Gonzalez R, Johnson TK, Bloedow DC, Maddock SW, et al. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology. 1991 May; 179(2):509-12.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)